Matinas BioPharma Holdings, Inc. — FY 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. This is an annual filing, not a standalone fourth-quarter report; quarterly results are not clearly provided in the filing text.
Business context
Matinas is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its lead programs are MAT9001, a prescription omega-3 candidate for severe hypertriglyceridemia, and MAT2203, an oral amphotericin B formulation using its lipid nano-crystal (LNC) delivery platform. The company also pursues LNC collaborations, including in gene therapy. MAT2501 development was temporarily halted to prioritize MAT9001, MAT2203, and platform work.
Financial results and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Contract research revenue | $0.120 million | $0.150 million |
| Research and development expense | $6.787 million | $9.010 million |
| General and administrative expense | $7.979 million | $7.642 million |
| Operating loss | $14.647 million | $16.502 million |
| Net loss | $14.083 million | $15.486 million |
| Net loss per common share, basic and diluted | $0.15 | $0.36 |
| Net cash used in operating activities | $10.321 million | $11.460 million |
| Net cash used in investing activities | $0.536 million | $0.942 million |
| Net cash provided by financing activities | $15.867 million | $15.603 million |
At year-end, cash and cash equivalents were $12.447 million; restricted cash was $0.561 million. Current assets were $13.085 million and current liabilities $2.840 million. Total liabilities were $3.802 million, including a $0.200 million note payable and lease liabilities. The company reported no product revenue, so product gross margins are not applicable.
Cash and cash equivalents plus restricted cash increased by $5.010 million during 2018, principally reflecting equity financing. The company raised $7.1 million net from Series B preferred stock and $9.2 million net through its ATM program. After year-end, a March 2019 common-stock offering and partial over-allotment generated approximately $30.5 million in net proceeds combined, according to the filing.
Changes versus FY 2017
- Net loss narrowed to $14.083 million from $15.486 million; loss attributable to common shareholders was $14.988 million versus $32.836 million. The prior-year common-shareholder loss included a $16.741 million warrant-inducement charge.
- R&D expense declined by $2.223 million, mainly from lower clinical-development and compensation costs, partly offset by higher preclinical expense and a full year of the new laboratory and manufacturing facility.
- G&A expense rose by $0.337 million, primarily because of higher compensation and insurance costs.
- Operating cash use decreased by approximately $1.138 million. Common shares outstanding rose from 93.4 million to 113.3 million during 2018.
Outlook, commentary, and significant risks
- MAT9001: Management planned to reactivate its IND in Q2 2019 and pursue a 505(b)(2) pathway. Planned 2019 work included comparative toxicology and bioavailability studies, followed by an FDA meeting to discuss a potential Phase 3 severe-hypertriglyceridemia study. A second head-to-head study versus Vascepa was expected to produce topline data in H2 2020. These are plans, not assured milestones.
- MAT2203: The company shifted its initial development focus from prevention of invasive fungal infections in immunosuppressed patients to treatment of cryptococcal meningitis. An NIH-funded, University of Minnesota-led study in Uganda was anticipated to begin in H2 2019, subject to final protocol and regulatory steps. The filing describes earlier small clinical studies as encouraging, but further evidence and regulatory review are required.
- Funding outlook: Management said post-offering resources were expected to fund operations into 2020. The MD&A says through 2020, while the financial-statement note specifies through April 2020; the filing does not provide a single consistent runway date. The company expects continuing losses and may need further financing.
- Material risks: Both lead programs remain investigational; clinical, regulatory, manufacturing, and commercialization outcomes are uncertain. MAT9001 relies on third-party manufacturers, while MAT2203 depends in part on NIH and other partners. The company lacks a sales and marketing organization and faces competition, reimbursement and pricing uncertainty, and intellectual-property and financing risks.
- Dilution and contingent obligations: Outstanding options, warrants, and convertible preferred stock may dilute common shareholders. Series A preferred stock carries accrued dividends and contingent royalty rights tied to MAT2203/MAT2501 sales or licensing; preferred-stock terms also provide for future share dividends.
- Controls and reporting: Management concluded internal control over financial reporting and disclosure controls were ineffective at year-end due to material weaknesses, including inadequate formal controls and insufficient accounting expertise in areas such as taxes, convertible securities, and stock compensation. A remediation plan was initiated; the auditor did not opine on control effectiveness.
- The company reported no pending legal proceedings. It had $6.085 million in future minimum lease payments, and its cash balances exceeded FDIC insurance limits during 2018.
Important facts for investors to verify
- Confirm the actual cash runway and spending assumptions, given the differing runway statements and planned clinical costs.
- Track MAT9001 IND reactivation, FDA feedback, study initiation, and whether the proposed 505(b)(2) evidence package is accepted.
- Verify MAT2203 trial protocol, start date, funding scope, and whether the Uganda study can support a registration pathway.
- Review subsequent share issuance, preferred-stock conversion and dividend terms, options and warrants, and the potential Series A royalty burden.
- Assess progress in remediating the disclosed material weaknesses and monitor future filings for any corrected or revised financial disclosures.